News BioAtla, Inc.

Equities

BCAB

US09077B1044

Real-time Estimate Cboe BZX Other stock markets 09:44:46 02/05/2024 pm IST			5-day change	1st Jan Change
2.99 ^USD	-11.28%		+34.44%	+22.97%

27/03	HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating	MT
26/03	Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	25/04	AQ
HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating	27/03	MT
Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024	27/03
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	27/03	AQ
BioAtla, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/03	CI
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024	19/03	AQ
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	07/03	AQ
Transcript : BioAtla, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM	11/01
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	22/12	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	22/12	MT
BioAtla Rallies After CEO Buys 50,000 Shares	21/12	MT
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	20/12	GL
Transcript : BioAtla, Inc. - Special Call	18/12
BioAtla, Inc.(NasdaqGM:BCAB) dropped from NASDAQ Biotechnology Index	15/12	CI
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types	13/12	AQ
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types	13/12	CI
Transcript : BioAtla, Inc. - Special Call	13/12
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023	06/12	AQ
Sector Update: Health Care Stocks Slipping Tuesday Afternoon	06/12	MT
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy	05/12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioAtla, Inc.

Equities

BCAB

US09077B1044

Summary

Filters